PMX 60056 by Falconer66a

Once PMX 60056 gets FDA approval, the entire surgical bleeding phenomenon changes. Yes, PMX 60056 just utterly stops or reverses the anti-clotting effects of heparin, without side effects—something that surgeons want to do just as soon as they end sew-up after a surgery.
But the much bigger thing is this. Heparin works wonderfully in stopping surgically-induced or surgically-coincidental blood clots. But the problem with heparin is that its anticoagulant properties continue unabated for a long time after surgery, allowing unwanted post-surgical bleeding. During surgery, physicians don’t want blood to be clotting anywhere in the body. At the surgical site, such bleeding can be stopped by cauterization or the tying off of larger blood vessels. No problem there. The surgeons can deal with surgical field bleeding. But after a surgery where heparin has been used, to keep clots from forming in other parts of the body, the risk of post-surgical bleeding can be significant (depending on the surgery). Consequently, heparin, right now, has limited usage, primarily because the present agent of reversing its anticoagulent properties, protamine, has a bunch of unwanted side effects.

Therefore, heparin, as good as it is, is used only when absolutely required, with well-known risks. When PMX 60056 becomes available, the entire surgical anticoagulant game is very likely to change, as the risks diminish markedly. With a syringe of 60056 in a surgical technician’s hands awaiting sew-up, the surgeon can rather freely administer heparin at the start. With PMX 60056, heparin is likely to be used much more commonly, perhaps by an order of magnitude.

Consequently, no one knows with any exactitude how big the PMX 60056 market will be. But surely it will larger than that of current heparin usage. As with other PolyMedix products, the medical game changes with PMX 60056.